AVBP
ArriVent BioPharma Inc.
$20.35
+$0.29(+1.45%)
57
Overall
60
Value
54
Tech
--
Quality
Market Cap
$738.11M
Volume
164.69K
52W Range
$15.47 - $30.41
Target Price
$39.22
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2024 Dec |
|---|---|---|---|---|
| OPERATING EXPENSES | ||||
| Operating Expenses | $36.9M | $94.3M | ||
| Research & Development | $30.4M | $79.0M | ||
| Research Expense | $30.4M | $79.0M | ||
| Selling, General & Administrative | $6.5M | $15.3M | ||
| General & Administrative Expenses | $6.5M | $15.3M | ||
| Salaries & Wages | -- | $3.2M | ||
| Other Operating Expenses | -- | $200.0K | ||
| OPERATING INCOME | ||||
| Operating income | $-36.9M | $-94.3M | ||
| EBITDA | -- | $-80.5M | ||
| NON-OPERATING ITEMS | ||||
| Gain on Sale of Securities | -- | $13.8M | ||
| Other Income/Expense | -- | $-13.8M | ||
| PRE-TAX INCOME | ||||
| EBIT | -- | $-80.5M | ||
| Pre-Tax Income | $-36.9M | $-80.5M | ||
| NET INCOME | ||||
| Net Income | $-36.9M | $-80.5M | ||
| Net Income (Continuing Operations) | $-36.9M | $-80.5M | ||
| Net Income (Discontinued Operations) | $-36.9M | $-80.5M | ||
| Net Income (Common Stockholders) | $-36.9M | $-80.5M | ||
| Normalized Income | -- | $-79.7M | ||
| TOTALS | ||||
| Total Expenses | $36.9M | $94.3M | ||
| SHARE & EPS DATA | ||||
| Average Shares Outstanding | $1.3B | $31.5M | ||
| Average Shares Outstanding (Diluted) | $1.3B | $31.5M | ||
| Shares Outstanding | $40.6M | $34.0M | ||
| Basic EPS | $-0.03 | $-2.56 | ||
| Basic EPS (Continuing Operations) | $-0.03 | $-2.56 | ||
| Diluted EPS | $-0.03 | $-2.56 | ||
| Diluted EPS (Continuing Operations) | $-0.03 | $-2.56 | ||
| OTHER METRICS | ||||
| Other Gand A | $6.5M | $15.3M | ||
| Rent And Landing Fees | -- | $-200.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVBP | $20.35 | +1.4% | 164.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |